CardioDx Announces Podium Presentations at American Heart Association Scientific Sessions 2011
PALO ALTO, Calif. – November 3, 2011 – CardioDx, a pioneer in the field of cardiovascular genomic diagnostics, today announced that data related to Corus® CAD, the company’s blood-based gene expression test for ruling out obstructive coronary artery disease in stable symptomatic patients, will be presented at the American Heart Association Scientific Sessions 2011 conference taking place November 12-16 in Orlando, Fla.
Corus CAD has now been used in more than 20,000 patients to assess whether or not their symptoms are due to obstructive coronary artery disease. With a simple blood draw, the Corus CAD test provides actionable information that helps clinicians make better decisions, helps patients avoid unnecessary procedures and radiation exposure, and helps payers address a major expense category.
On Monday, November 14 at 9:15 a.m. ET in room W109a, Szilard Voros, M.D., Atlanta, GA will give an oral presentation entitled “Validation of a Gene Expression Test Score using Coronary Artery Calcium and CT-Angiography as Reference Standard for Plaque Burden and Stenosis Evaluation.” This second validation study assessed the Corus CAD gene expression testing performance in 256 patients undergoing coronary artery calcium (CAC) and 237 patients undergoing CT coronary angiography (CTA).
On Tuesday, November 15 at 11:15 a.m. ET in room W104, James A. Wingrove, Ph.D., senior director of research for CardioDx, will deliver an oral presentation entitled “Exploration of a Whole Blood Gene Expression-Based Surrogate Test for Smoking Status.” This study evaluates the ability of a genomic-based predictor to provide further insight into the body’s response to smoking.
On Tuesday, November 15 at 2:30 p.m. ET in room W103, Gregory S. Thomas, M.D., M.P.H., clinical professor of medicine and director of nuclear cardiology education at the University of California-Irvine School of Medicine, will provide an oral presentation of the results of “The COMPASS Trial: A Prospective Multi-Center, Double-Blind Study Assessing a Whole Blood Gene Expression Test for the Detection of Obstructive Coronary Artery Disease in Symptomatic Patients Referred for Myocardial Perfusion Imaging (MPI).” The COMPASS trial represents a third independent validation cohort for Corus CAD, comparing the test to MPI in a population of stable symptomatic patients with suspected obstructive coronary artery disease.
About Corus CAD
Corus CAD is the first and only clinically validated blood-based test for obstructive coronary artery disease. The test involves a routine blood draw conveniently administered in the clinician’s office and does not expose patients to risks of radiation or imaging agent intolerance. Corus CAD is a decisionmaking tool that can help primary care clinicians and cardiologists rule out obstructive coronary artery disease as the cause of a nondiabetic patient's symptoms. It is the first sex-specific test for obstructive coronary artery disease, accounting for critical biological differences between men and women.
Findings from the PREDICT validation study of the Corus CAD gene expression test were published in 2010 in the Annals of Internal Medicine, the journal of the American College of Physicians. The test has been honored as a winner of The Wall Street Journal’s prestigious Technology Innovation Awards and one of TIME’s Top Ten Medical Breakthroughs.
The Corus CAD test measures the RNA levels of 23 genes from a whole blood sample. Because these RNA levels are increased or decreased when obstructive coronary artery disease is present, the Corus CAD score indicates the likelihood that an individual patient does not have obstructive coronary artery disease.
Corus CAD is commercially available through an innovative patient sample kit that includes everything needed for blood collection and express delivery to the company’s CLIA-certified Palo Alto, Calif. laboratory. Test results are delivered promptly to the clinician’s office. Corus CAD is currently available in the United States.
For more information please visit http://www.cardiodx.com/media-kit/.
About Gene Expression Testing
Gene expression testing provides valuable tissue and cell-specific information about the molecular mechanisms involved in disease processes, enabling evaluation of an individual patient’s disease state, activity, and/or progression at a given point in time. Unlike genetic tests, which measure genetic variations, mutations, traits and predispositions—factors that are constant over a person’s lifetime— gene expression testing assesses a dynamic process, integrating both genetic predisposition and additional behavioral and environmental influences on current disease state.
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. For more information, please visit www.cardiodx.com.